Meet the team at Booth #409 

Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.

 

 
 

Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.

The clinical data compiled by GlobalData for Novoteoch also found that:

“By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan. 

In the APAC region, the proportion of oncology trials doubled during 2017-2021. 

In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy.”

Download the Reports Here:

IMMUNO-ONCOLOGY – ASIA PACIFIC – CLINICAL TRIAL LANDSCAPE

EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5

According to Yooni Kim, Vice President, Global Clinical Services Novotech: 

“Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes.”

“Novotech’s service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance.”  

Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

Media contact

데이빗 제임스 (David James)

언론 연락처

노보텍은 글로벌 실행 능력을 갖춘 아시아 태평양 중심의 선도적인 바이오텍 CRO 기업으로 국제적으로 인정받고 있습니다.

노보텍은 연구소, 임상1상 시험 기관, 약물 개발 컨설팅 서비스(DDC, Drug Development Consulting) 그리고 FDA 규제 전문성을 갖춘 임상 CRO 기업으로 1상에서부터 4상까지의 임상시험과 생물학적 동등성 시험을 포함하여 5,000건 이상의 임상 프로젝트에 참여한 경험이 있습니다.  노보텍은 아시아 태평양, 미국, 유럽에서 임상시험을 수행하고자 하는 바이오텍 고객들에게 서비스를 제공할 수 있습니다. 노보텍은 전 세계적으로 3,000명 이상의 직원과 34개의 사무실을 보유하고 있습니다.

보다 자세한 내용은 https://novotech-cro.com/contact를 통해 확인하실 수 있습니다.